Daxor Corporation to Present at the 31st Annual Roth Conference on March 19, 2019
March 15 2019 - 8:30AM
Daxor Corporation
(NYSE MKT: DXR) an investment
company with innovative medical instrumentation and biotechnology
operations focused on blood volume measurement, today announced
that Michael Feldschuh, CEO, will be a featured presenter at the
ROTH Capital Partners 31st Annual Growth Stock Conference on
Tuesday, March 19, 2018 at 11:00 AM Pacific Time in PINK – SALON 5
at the Ritz-Carlton in Laguna Niguel, CA.
Mr. Feldschuh will provide an overview of the
company’s business model and growth strategy and will be available
for one-on-one meetings.
About Daxor Corporation
Daxor Corporation is an innovative medical
instrumentation and biotechnology company. We manufacture the
BVA-100 Blood Volume Analyzer, the first instrument cleared by the
FDA to provide rapid direct measurement of a patient’s blood
volume. We believe that the BVA-100 Blood Volume Analyzer has the
potential to transform therapy in a broad range of surgical and
medical conditions. It is our goal, working in conjunction with
hospitals and clinics, to achieve that possibility. Ultimately the
company’s mission is to help hospitals and physicians incorporate
Daxor’s BVA-100 diagnostic into standard clinical practice. For
more information please visit our website at
http://www.daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Investor Relations Contact:Bret ShapiroSr. Managing PartnerCORE
IR561-479-8566brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024